After Morgan Stanley and Piper Jaffray gave SAGE Therapeutics (NASDAQ: SAGE) a Buy rating last month, the company received another Buy, this time from RBC Capital. Analyst Brian Abrahams reiterated a Buy rating on SAGE Therapeutics yesterday and set a price target of $255. The company’s shares closed yesterday at $151.20.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 12.3% and a 55.1% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, Alder Biopharmaceuticals, and Intra-Cellular Therapies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for SAGE Therapeutics with a $217.43 average price target, representing a 43.8% upside. In a report issued on August 6, Piper Jaffray also initiated coverage with a Buy rating on the stock with a $206 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $195.97 and a one-year low of $59.57. Currently, SAGE Therapeutics has an average volume of 532K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.